Poor reporting and non-disclosure of data in randomized trials of heart failure drugs prevented researchers from completing a systematic review of these treatments.
Absolute Event Rate: 0% vs 0%
When Robert Fleetcroft and colleagues attempted a systematic review of the treatment of heart failure, they were unable to answer their research question because of poor reporting and non-disclosure of data. And yet the necessary studies had been done. Here they discuss their experience and possible solutions
Fleetcroft et al. (Wed,) reported a other. Poor reporting and non-disclosure of data in randomized trials of heart failure drugs prevented researchers from completing a systematic review of these treatments.